The change practice successes of anti-PD-(L)1 and anti-CTLA4 agents in the management of advanced non-oncogene-addicted NSCLC [1,2] are examples that offer a promising direction to develop new target immunotherapies for B7-H3. The gene discussed is CD274; the disease is non-small cell lung carcinoma.